GYRE (Gyre Therapeutics) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 27, 2026)


GYRE Gyre Therapeutics Inc GYRE
39 GF Score
Price $6.30
GF Value $9.82
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Gyre Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

GYRE vs CBIO, RIGL, ARVN: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Gyre Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Margin of Safety % (DCF FCF Based) falls into.


GYRE
39GF Score
Gyre Therapeutics Inc GYRE
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $6.30 is trading 35.8% below its estimated GF Value™ of $9.82. GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.

Key valuation signals for GYRE:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $9.82 vs. price of $6.30 (35.8% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score

Get the complete analysis for GYRE

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.30
Price
$9.82
GF Value